Pharvaris Director Trims Stake Ahead of Key 2026 Clinical Milestones

Pharvaris N.V. (PHVS) director Johannes Gerardus Christiaan Petrus Schikan has reduced his direct equity position in the clinical-stage biopharmaceutical company through a series of open-market transactions. According to a recent SEC Form 4 filing, Schikan sold 7,100 shares over two days, totaling approximately $213,000. The transactions, executed at a weighted average price of $30.05 per share, were carried out under a Rule 10b5-1 trading plan. This scheduled divestment represents only 1.80% of Schikan's direct holdings, leaving him with 388,067 shares. As of April 23, 2026, his remaining direct position was valued at approximately $10.59 million. While insider sales often draw scrutiny, the limited scale of this transaction suggests it is a routine portfolio adjustment rather than a signal of declining confidence. Pharvaris remains focused on its pipeline of oral therapies for rare diseases, specifically targeting hereditary angioedema (HAE). Market participants are looking past the insider activity toward two critical catalysts in 2026. The company expects to release topline data from its pivotal Phase 3 CHAPTER-3 study of deucrictibant XR in the third quarter. Additionally, Pharvaris plans to submit a U.S. New Drug Application (NDA) for deucrictibant IR for on-demand HAE treatment during the first half of the year. For a clinical-stage entity with no current revenue, these regulatory and clinical milestones are expected to be the primary drivers of stock volatility.